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Abstract
Leptin is known to exert cardiodepressive effects and to induce left ventricular (LV) remodelling. Nevertheless, the autocrine and/or
paracrine activities of this adipokine in the context of post-infarct dysfunction and remodelling have not yet been elucidated. Therefore,
we have investigated the evolution of myocardial leptin expression following myocardial infarction (MI) and evaluated the consequences
of specific cardiac leptin inhibition on subsequent LV dysfunction. Anaesthetized rats were subjected to temporary coronary occlusion.
An antisense oligodesoxynucleotide (AS ODN) directed against leptin mRNA was injected intramyocardially along the border of the
infarct 5 days after surgery. Cardiac morphometry and function were monitored by echocardiography over 11 weeks following MI.
Production of myocardial leptin and pro-inflammatory cytokines interleukin (IL)-1 and IL-6 were assessed by ELISA. Our results show
that (1) cardiac leptin level peaks 7 days after reperfused MI; (2) intramyocardial injection of leptin-AS ODN reduces early IL-1 and 
IL-6 overexpression and markedly protects contractile function. In conclusion, our findings demonstrate that cardiac leptin expression
after MI could contribute to the evolution towards heart failure through autocrine and/or paracrine actions. The detrimental effect of 
leptin could be mediated by pro-inflammatory cytokines such as IL-1 and IL-6. Our data could constitute the basis of new therapeutic
approaches aimed to improve post-MI outcome.
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Introduction
The adipokine leptin was primarily described as a satiety regulatory
metabotropic hormone, mainly produced by adipocytes under
physiological conditions. Recently, leptin and its receptors (ObRs)
have been shown to be overexpressed in a variety of tissues includ-
ing the myocardium under conditions of ischemia/reperfusion
[1–3]. Several lines of evidence indicate that leptin has powerful
cardiac effects [4]. Nevertheless, reports are divided on whether
leptin has predominantly adverse or beneficial effects on the heart.
Leptin has been shown to decrease cardiac function through a
signal transducer and activator of transcription 3 (STAT-3)-nitric-
oxide-p38 mitogen-activated protein kinase (p38 MAPK)-depend-
ent mechanism [5] and to exert a direct hypertrophic effect
[6–10]. Moreover, in vivo continuous infusion of leptin following
myocardial infarction (MI) in mice causes eccentric dilation with
increased systolic function [10]. In addition, Purdham et al. have
recently shown that chronic ObR blockade by systemic injection of
specific antibodies limits the development of post-infarct cardiac
dysfunction in rats [11]. Conversely, blunting leptin signalling in
mice through leptin deficiency or ObR deficiency is associated
with progressive cardiac hypertrophy [12] and increased severity
of cardiac dysfunction and remodelling after MI [13]. In addition,
leptin has been shown to reduce infarct size in isolated perfused
rat hearts [14] and to attenuate cardiac apoptosis after ischemia
by increasing bcl-2 and survivin gene expression and by reducing
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caspase-3 activity [15]. Therefore, the cardiovascular effects of leptin
are very complex, and translating basic research studies to human
physiology is very difficult, particularly in this area of research.
Clinical data have reported that elevated circulating leptin lev-
els are associated with greater risk of congestive heart failure and
cardiovascular disease at least in elderly [16]. Moreover, it has
been demonstrated that human serum leptin level reaches a peak
value on the second day of hospitalization after MI [17]. These
observations suggest that leptin might be involved in the patho-
physiological processes leading to cardiac dysfunction and
adverse remodelling after MI in human beings.
The aim of the present study was first to determine the profile
of cardiac leptin production in a model of reperfused MI in rats.
Therefore, myocardial leptin level was assessed by Chemiarray® at
different time-points over 10 days after the surgical induction of
temporary cardiac ischemia. This preliminary experiment has
allowed us to demonstrate a transient peak of leptin cardiac con-
tent, reaching a maximum 7 days after reperfused infarction. The
second step of the study has consisted in specifically inhibiting
post-infarct cardiac leptin production by use of a specific antisense
oligodeoxynucleotide (AS ODN) directed against leptin mRNA and
directly injected in the myocardial wall, along the border of infarc-
tion. This study was designed to evaluate the autocrine and/or
paracrine effects of leptin in the heart on long-term cardiac dys-
function without affecting extracardiac leptin activity.
Materials and methods
Reperfused MI
Adult male Wistar rats (250–350 g body wt; Charles River, L’Arbresle Cedex,
France) were maintained on a standard diet and cared for according to the
guiding principles in the care and use of animals (European Communities
Council Directive L358-86/609/EEC, November 1986). All protocols involv-
ing living animals were performed under the license from the French
authorities (license number A38018).
Rats were anaesthetized intraperitoneally with a mixture of ketamine
(50 mg/kg) and xylazine (10 mg/kg). Rats were rapidly intubated and
mechanically ventilated (tidal volume: 1 ml/100 g body weight; ventilation
rate: 65 strokes/min.) with a mixture of isoflurane (0.5%; AErrane®,
Lessins, Belgium) and oxygen (20%) in room air (79.5%). Experimental MI
was performed as previously described [18]. A left thoracotomy was per-
formed at the fourth intercostal space and the heart was briefly exteriorized
by digital pressure on the chest wall. The left coronary artery was ligated
1–2 mm from its origin. The heart was then quickly returned to the chest
cavity. After 1 hr of occlusion, the ligation was removed and the left coro-
nary artery reperfused.
Time course of changes in leptin cardiac content
Following left coronary artery occlusion and reperfusion, rats were killed 3,
5, 7, 8 or 10 days after MI. And heart samples were quickly frozen at liq-
uid nitrogen temperature and stored at –80C until assay. Frozen samples
(200–400 mg) were crushed into liquid nitrogen and homogenized in a Tris
(25 mM)-ethylenediaminetetraacetic acid (2 mM) buffer (pH 7.4) adapted
from Guo et al. [19], and containing a protease inhibitor cocktail 1/200
(P2714; Sigma-Aldrich, L’Isle d’Abeau Chesnes, France), and Triton X-100
(0.5%). After incubation for 2 hrs at 4C, this suspension was centrifuged
for 30 min. at 14,000  g at 4C to remove cellular debris. Protein content
was determined using a BCA protein assay kit (Pierce, Rockford, IL, USA).
Myocardial leptin levels were assessed by Chemiarray™ according to
the manufacturer’s instructions (Rat Cytokine Antibody Array I; Chemicon-
Millipore, Inc., Billerica, MA, USA). Briefly, membranes were incubated 
for 30 min. in 10 mM Tris buffer (5% bovine serum albumin, 0.15 M NaCl,
pH 7.6) and for 1 hr with protein extracts in presence of biotinylated anti-
bodies. Membranes were then washed and incubated for 30 min. with
horseradish peroxidase (HRP)-conjugated streptavidin. Membranes were
revealed with enhanced chemiluminescence (ECL).
For each group, the same amount of cardiac extract from three differ-
ent hearts were mixed and incubated with the membrane, as previously
described [18]. Membranes were scanned and blot-intensities (arbitrary
units) were measured using ImageJ 1.37. Optical density of each spot was
expressed as a percentage of a specific positive internal standard (after
subtraction of background).
Cardiac leptin inhibition with antisense
oligodeoxynucleotides
Specific anti-leptin AS ODN and inactive random ODN [Control ODN, 
nearly same length and guanine-cytosine (GC) content] were designed and
manufactured by Biognostik (Antisense custom design kit, accession n :
MN-013076; Biognostik, Göttingen, Germany). AS ODN and Control ODN
were stored in sterile phosphate buffer at 4C until use.
Five days after coronary artery occlusion and reperfusion, rats were
anaesthetized and ventilated. The fourth intercostal space was reopened
and the heart was briefly exteriorized by digital pressure on the chest wall.
Control ODN or AS ODN (0.1 mM solution) was rapidly injected in the
myocardial wall in the border of the infracted area. Each animal received
five intramyocardial micro-injections of ODN solution (total injected vol-
ume: 0.15 ml). No mortality was observed during this protocol.
Echocardiographic follow-up
Two-dimensional targeted M-mode recording was obtained from the short
axis view of the heart at the level of the papillary muscle using a 15-7 MHz
probe (HP21380A; Agilent Technology, Philips Systèmes Médicaux,
France) connected to a Helwett Packard Sonos 5500. TM-mode measure-
ments of the LV end-diastolic (LVEDD) and LV end-systolic (LVESD)
dimensions were made according to the recommendations formulated by
the American Society of Echocardiography. The percentage of LV fractional
shortening (LVFS) was calculated as LVFS (%)  ([LVEDD –
LVESD]/LVEDD)  100.
Ex vivo determination of LV pressure–volume curves
Seven or 77 days after the surgical induction of infarction, rats were anaes-
thetized with ketamine (50 mg/kg) and xylazine (10 mg/kg) and passive
pressure–volume characteristics of the LV were evaluated post-mortem as
previously described [20]. A saturated solution of potassium chloride was
injected into the vena cava until the heart stopped. The heart was then
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excised and a cannula, connected to a pressure transducer (P23XL; Statham
Instruments, Hato Ray, Puerto Rico), was inserted 5 mm into the LV through
the aorta. The right and left atrioventricular junctions, the pulmonary artery
and vena cava were ligated and physiological saline was infused in the 
LV at a constant flow rate of 0.68 ml/min. while intraventricular pressure
was continuously monitored from 0 to 40 mmHg. The operating LV end-
diastolic volume (OLVEDV) was determined from the LV pressure–volume
curve and defined as the volume corresponding to a filling pressure equal
to in vivo end-diastolic pressure.
Assessment of infarct size
Hearts were frozen in liquid nitrogen and cut at –20C with a cryostat
(Microm HM505E; Microm International GmbH, Walldorf, Germany). Three
20-m-thick transverse sections were obtained at 5.36 mm from the basis
of the ventricles of each frozen heart. Each frozen section was stained
using nitro blue tetrazolium (0.04% in 0.05 mol/l sodium succinate buffer,
pH 7.6). Necrotic and non-necrotic tissues were distinguished by the
absence or presence of staining respectively, and the endocardial and epi-
cardial lengths, as well as total areas of necrotic and non-infarcted muscles
were estimated by planimetry.
Estimation of myocardial leptin, interleukin (IL)-6
and IL-1 by ELISA
Leptin, IL-6 and IL-1 were assessed using ELISA kits (leptin/IL-6/IL-1
Duoset; R&D Systems, Abingdon, UK), and expressed as pg/mg protein.
Statistical analysis
Values are expressed as means  SEM. One way analysis of variance was
performed to determine significant differences between groups. The 
significance of the difference between the means of the groups was tested
with Fisher’s a posteriori protected least significant difference test. 
P  0.05 was considered as the threshold of statistical significance.
Results
Time course of changes in myocardial leptin 
content after reperfused MI
Myocardial leptin level, measured by cytokine array, progressively
increased from day 3 after MI to reach a maximum (380% 
versus non-operated) at day 7, before returning to non-operated
baseline level at day 10 (Fig. 1).
Effects of cardiac leptin inhibition on after MI
There was no significant difference in infarct size between Control
ODN-treated (35.16  1.86) and AS ODN-treated (35.74  2.26)
groups 1 week and 11 weeks after reperfused infarction (1 week
after MI: Cont ODN  35.16  1.86 versus AS ODN  35.74 
2.26, ns; 11 weeks after MI: Cont ODN  36.60  4.16 versus AS
ODN  3.88  6.99, ns). Body weight and food intake were equiv-
alent in both groups (data not shown) over the 11 week follow up.
In order to verify that ODNs were still present in the
myocardium 2 days after injection, control rats were injected with
Fluoresceine isothiocyanate (FITC)-labelled ODNs, 5 days after MI.
Two days after FITC-ODN injection, rats were killed and their
hearts were placed under a fluorescence camera (EMCCD 512 
512 Hamamatsu Orca – Macro Fluo 512  512; Hamamatsu
Photonics, Massy, France) and illuminated at 488 nm (Cube FITC
Leica, Leica Mycrosystemes SAS, Nanterre, France). Compared to
untreated hearts (Fig. 2A), FITC-ODN injected hearts exhibited dif-
fuse fluorescence as well as focal hot spots corresponding to the
points of injection (Fig. 2B and C).
Myocardial leptin, measured by ELISA, was significantly
reduced 7 days after the initial surgical protocol in AS ODN-
Treated rats compared to Control ODN-treated rats (Fig. 3A).
Myocardial IL-1 (Fig. 3B) and IL-6 (Fig. 3C), measured by ELISA,
Fig. 1 Evolution of cardiac leptin level during 
the first 10 days following reperfused MI.
Chemiarray™: Blot intensities are expressed as a
percentage of positive specific internal controls.
n  3 hearts per point.
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were markedly reduced 7 days after reperfused infarction in the AS
ODN-treated group compared to the Control ODN-treated group.
Echocardiographic measurements
In rats treated with Control ODNs, MI induced a rapid decrease in
LV contractility (Fig. 4) which slowed down after the second week
after surgery, giving a characteristic exponential curve. The treat-
ment with anti-leptin ODNs completely stopped the deterioration
of LV contractility. As a consequence, 77 days after the initial
reperfused infarction, LVFS (%) in AS ODN-treated rats was 80%
higher than LVFS in Control ODN rats (Fig. 4A).
Pressure–volume curves
LV pressure–volume curves measured ex vivo in potassium
arrested hearts are shown in Figure 5A. Pressure–volume curves
were equivalent in Control ODN and AS ODN-treated groups at day
7 after reperfused MI. After 77 days of reperfusion, a significant
rightward shift of the curves for both groups was found compared
with the curves obtained at day 7, indicating an increase in LV
compliance. At day 77, the increase in LV compliance was less
severe in AS ODN-treated rats than in Control ODN-treated rats. In
Control ODN-treated rats, OLVEDV was also significantly
increased 77 days after reperfused MI compared with 7 days after
surgery (Fig. 5B) indicating an increase in LV volume. AS ODN-
treatment totally prevented the increase in OLVEDV between the
7th and the 77th day after MI (Fig. 5B).
Discussion
Our experimental model of temporary left coronary artery ligation
in rats induces a transient increase in myocardial leptin level, 
7 days after reperfused MI. The inhibition of this peak of leptin
production by specific AS ODNs reduces the expression of cardiac
pro-inflammatory cytokines IL-1 and IL-6 and markedly reduces
LV dysfunction.
Leptin neutralization after myocardial infarction
Leptin has been shown to exert a negative inotropic effect on ven-
tricular myocytes via increased nitric oxide production [5, 21], as
well as to induce cardiac hypertrophy [6, 12]. On this basis some
authors have suggested that ObR blockade could reduce cardiac
hypertrophy and improve post-infarct cardiac function [11]. Therefore,
they have tested the effects of chronic systemic administration
Fig. 2 Localization of ODNs two days after intramyocardial injection. Rats were subjected to reperfused MI. Control unlabelled ODNs or FITC-labelled
ODNs were injected in the border of the infarct, five days after surgery. Two days after ODN injection, rats were killed and their hearts were placed under
a fluorescence camera (EMCCD 512  512 Hamamatsu Orca – Macro Fluo 512  512) and illuminated at 488 nm (Cube FITC Leica). (A) Rat heart injected
with Control unlabelled ODNs; Rat heart injected with FITC-labelled ODNs: left view (B), right view (C).
Fig. 3 Effect of antisense leptin inhibition on
leptin, IL-1 and IL-6 myocardial levels, 7 days
after reperfused MI. Leptin (A), IL-1 (B) and
IL-6 (C) ELISA assays on six to seven hearts per
group. Open bars: Control ODN-treated group;
Full bars: AS ODN-treated group. Means  S.E.M.
*P 	 0.05 versus Control ODN-treated group.
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(daily i.v. injection) of anti-ObR antibodies, in a rat model of per-
manent coronary occlusion, over a time period of 4 weeks after MI
[11]. Although this study has reported beneficial effects of the
treatment, its translation to the human pathology of infarction is
very difficult for several reasons. First, if leptin contributes to
post-infarct cardiac dysfunction and heart failure, it is probably via
an autocrine or paracrine mechanism [4]. Therefore, the anti-leptin
treatment should have been targeted to the heart to avoid any
interference with the physiological endocrine activity of the hor-
mone. Second, the treatment should have been limited in duration
to the time period during which endogenously produced leptin
exerts its autocrine or paracrine detrimental action to the heart.
Contrarily to this previous systemic approach, our study fulfils
these two criteria since the AS ODN-treatment is restricted to the
myocardium and limited to the period of time during which leptin
cardiac content was found to increase after reperfused MI. Indeed,
phosphorothioate oligodeoxynucleotides have been shown to be
metabolized in living tissues and slowly eliminated within 2–7 days,
depending on the organ [22]. Therefore, the AS ODNs used in our
study might not affect the endocrine activity of leptin since our
treatment does not modify food intake. Nevertheless, since we
have not monitored leptin expression throughout the protocol, we
cannot exclude the possibility that our short-term ODN treatment
could have induced profound phenotypic modifications influenc-
ing long-term cardiac expression of leptin.
Leptin and proinflammatory cytokines
ObRs have been shown to be induced locally in the heart after a
sequence of ischemia and reperfusion [1, 3]. Consistently with
these previous reports, the present study shows that after tempo-
rary left coronary artery ligation in the rat, cardiac leptin level is
increased up to 4-fold compared with basal values. Moreover, our
study of the time course of cardiac leptin production after reper-
fusion indicates that this phenomenon peaks 7 days after reper-
fused MI and decreases thereafter. Interestingly, several experi-
mental studies have reported a transient myocardial increase in
the expression of diverse proinflammatory cytokines 1 week after
MI in the same rat model [18, 19, 23]. In addition, Berthonneche
et al. [20] have demonstrated that some of these cytokines con-
tribute significantly to the development of subsequent LV dysfunc-
tion and heart failure since their inhibition durably protects cardiac
function after MI. A direct link between leptin and pro-inflamma-
tory cytokine production has already been demonstrated in several
experimental studies. Notably, leptin induces IL-1 and IL-6 in dif-
ferent cell types [24–27]. In the rat model of reperfused MI, IL-6
and IL-1 are transiently over produced 8 days after surgery [18].
In our study, the injection of leptin AS ODNs 5 days after surgery
totally prevented the increase in cardiac IL-6 and IL-1 measured
7 days after reperfused MI. Our results therefore suggest that lep-
tin accumulation in the myocardium after reperfused MI could
Fig. 4 Effects of antisense leptin inhibition on
cardiac contractility during the 11 week follow-
up. (A) Echocardiographic measurement of
LVFS; open circles: Control ODN-treated group;
full circles: AS ODN-treated group; means 
S.E.M.; n  6–10 rats per group; *P 	 0.05,
**P 	 0.01 versus Control ODN-treated group.
(B) Representative M-mode echocardiographic
images. LVEDD  left ventricular end diastolic
diameter; LVESD  left ventricular end systolic
diameter.
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contribute to LV dysfunction and subsequent heart failure, at 
least in part through the induction of pro-inflammatory cytokine
expression.
Cardiac sources of leptin
The present study demonstrates that reperfused MI induces a
transient increase in cardiac leptin content within the first week
after surgery. Nevertheless, the cell types responsible for leptin
production as well as the mechanisms by which leptin expression
is induced still remain to be determined. Leptin is traditionally
viewed as an adipocyte-released hormone with endocrine effects.
Nevertheless, several peripheral tissues, including the heart, are
known to produce leptin which can then exert autocrine or
paracine activities [1, 7]. Several in vitro studies have demon-
strated that cardiomyocytes are able to produce leptin under
diverse conditions of stress. Nevertheless, under pathophysio-
logical situations, other cell types such as pericardial (epicardial
plus paracardial adipose tissue [28]) and perivascular adipocytes,
can significantly contribute to cardiac leptin production. In small
rodents, pericardial fat is only present in obese animals and is
limited to a localized area around the pericardium, without any
direct contact with the cardiomyocytes [4]. Therefore, the peri-
cardial adipose tissue is probably not significantly involved in the
transient cardiac leptin expression that we have observed in our
study. In pathological states, perivascular fat can also secrete a
deleterious profile of adipokines, and leptin levels in this tissue
are thought to increase [29]. Nevertheless, the fact that direct
intramyocardial injections of anti-leptin ODNs totally abolished
the overproduction of leptin in our study strongly suggests 
that the origin of leptin is within the myocardium rather than
perivascular.
In conclusion, our study shows that transient production of
leptin in the myocardium after reperfused MI, contributes to the
development of LV dysfunction and subsequent heart failure,
through an autocrine or paracrine mechanism. Moreover, our
results suggest that the mechanism of action of leptin in this con-
text might involve the overexpression of proinflammatory
cytokines.
Fig. 5 LV pressure–volume curves (A) and
OLVEDVs (B) obtained ex vivo after potassium
arrest during saline infusion over a range of
pressure of 0–40 mmHg 7 or 77 days after
reperfused MI. OLVEDV: operating LV end-dias-
tolic volume; means  S.E.M.; n  5–9 rats per
group; **P 	 0.01 versus corresponding
Control ODN-treated group.
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